THM Capital Advisory advises WOMED on its €6m Series A
THM Capital Advisory acts as sole financial advisor to WOMED on its €6m Series A funded by private investors and the French fund IRDI. Womed is a Femtech startup company pioneering innovative, safe and effective treatments to free women from infertility and challenging uterine pathologies.
Womed was founded by healthtech entrepreneur Gonzague Issenmann, biomedical polymer specialist Prof. Xavier Garric and reproductive specialist Dr. Stephanie Huberlant, to commercialize an invention from Garric's Polymers for Health and Biomaterials lab at the University of Montpellier, France.
Its first product Womed Leaf™ is a medical device to treat and prevent bonding of the uterine walls after surgical intervention (intrauterine adhesions), which is responsible for infertility and obstetrical complications such as abnormal placentation. Womed Leaf™ obtained CE Mark according to the new European Regulation, and efficacy clinical trial data will be presented in H1-2024.
Based on its proprietary polymer technology, Womed also develops intrauterine drug delivery therapies for the treatment of fibroids, endometriosis and acute bleedings which affect hundreds of millions of women worldwide. Delivering well-known drugs directly in the uterine cavity where the pathology is located allows to increase efficacy while significantly reducing the systemic exposure compared to the oral route, hence limiting side effects.
The Series A will fund the commercial launch of the Leaf™ and the further development of its pipeline of proprietary intrauterine therapies.
FOUNDERS ADVISORS : Financial : THM Capital Advisory (Thomas Mitard, Juan Fernando Ramirez, Aurélien Prost, Paul Demorge); Legal: Villechenon (Morgan Hunault-Berret, Quentin Dupont)
INVESTORS ADVISORS : IP & Legal : LPA-CGR Avocats (Mathieu Selva, Stéphane Erard); Legal: White & Case (Alexandre Ippolito, Baptiste Ferraud); Legal: Raion (Claire Feller)